Evidence map›Paper›PMID 34439567›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Bilberry (

Matti Mauramo, Tuulia Onali, Wafa Wahbi, Jenni Vasara, Anniina Lampinen, Elina Mauramo, Anne Kivimäki, Stefan Martens, Hely Häggman, Meeri Sutinen and 1 more

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Nutrients · 2024
    Review
  6. Article
  7. Article
  8. Nutrients · 2023
    Review
  9. Article
  10. Molecules (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matti MauramoDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.ORCID 0000-0002-0107-4939
Tuulia OnaliDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.
Wafa WahbiDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.
Jenni VasaraDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.
Anniina LampinenDepartment of Ecology and Genetics, University of Oulu, 90570 Oulu, Finland.
Elina MauramoDepartment of Public Health, University of Helsinki, 00014 Helsinki, Finland.
Anne KivimäkiDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.
Stefan MartensFondazione Edmund Mach, Research and Innovation Center, TN, 380105 San Michele'all Adige, Italy.ORCID 0000-0001-9913-4882
Hely HäggmanDepartment of Ecology and Genetics, University of Oulu, 90570 Oulu, Finland.
Meeri SutinenCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu, 90570 Oulu, Finland.
Tuula SaloDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland.ORCID 0000-0001-6039-0088

Funding

Finnish Cancer InstituteSigrid Juséliuksen Säätiö
6 · The paper itself

Abstract

Previous studies indicate that bilberry with high amounts of phenolic compounds can inhibit carcinogenic processes of colorectal cancer in vitro and in vivo. However, no studies have focused on the effects of bilberry on oral cancer. In this study, we aimed to examine the effects of bilberry powder on oral squamous cell carcinoma (OSCC) cells using both in vitro and in vivo assays. The effects of 0, 1, 10, and 25 mg/mL of whole bilberry powder on the viability, proliferation, migration, and invasion of OSCC (HSC-3) cells were examined and compared with 0.01 mg/mL of cetuximab. Two oral keratinocyte cell lines served as controls. Tumor area was analyzed in zebrafish microinjected with HSC-3 cells and treated with 2.5, 10, or 25 µg/mL of bilberry powder. Metastases in the head or tail areas were counted. Bilberry powder inhibited the viability, proliferation, migration, and invasion of HSC-3 cells (

Indexed as

anthocyaninbilberrycarcinomainvasionmetastasismigrationoral cancerproliferationtumorigenesisviabilityzebrafish

Identifiers

PMID34439567
PMCPMC8389301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.